{
    "clinical_study": {
        "@rank": "122642", 
        "arm_group": [
            {
                "arm_group_label": "Probiotic", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Evidence have shown benefits of gut flora modulation in treatment of irritable bowel\n      syndrome (IBS), but few reports are available on the effects of multistrain probiotics and\n      there are few reports available in this regard from our society. Thus, we investigated if\n      probiotics are effective in our patients as well. We hypothesize that the multistrain\n      probiotic Balance containing seven bacteria species including Lactobacillus strains,\n      Bifidobacterium strains, and Streptococcus thermophiles reduces the symptoms of irritable\n      bowel syndrome."
        }, 
        "brief_title": "Probiotics in the Treatment of Irritable Bowel Syndrome", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Irritable Bowel Syndrome", 
        "condition_browse": {
            "mesh_term": "Irritable Bowel Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age between 18 and 65\n\n          -  diagnosis of IBS based on the Rome III criteria\n\n          -  willingness to participate\n\n        Exclusion Criteria:\n\n          -  receiving other probiotics compound during the study\n\n          -  receiving antibiotics during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "132", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01837472", 
            "org_study_id": "390506"
        }, 
        "intervention": [
            {
                "arm_group_label": "Probiotic", 
                "description": "Patients in the probiotic group received the probiotic compound Balance\u00ae (Protexin Co., Somerset, UK) or similar placebo, twice daily after meal for 14 consecutive days. Balance\u00ae capsules contains seven bacteria species including Lactobacillus strains (L. casei, L. rhamnosus, L. acidophilus, and L. bulgaricus), Bifidobacterium strains (B. breve and B. longum), and Streptococcus thermophiles. Total viable count (TVC) is 1 x 108 CFU/per capsule. Other Ingredients are Fructo-oligosaccharide as prebiotic, magnesium stearate, and hydroxypropyl methyl cellulose.", 
                "intervention_name": "Probiotic", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Patients in the placebo group received the placebo capsule twice daily after meal for 14 consecutive days.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Irritable bowel syndrome", 
            "Functional gastrointestinal disorders", 
            "Gut flora", 
            "Probiotics"
        ], 
        "lastchanged_date": "April 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Isfahan", 
                    "country": "Iran, Islamic Republic of", 
                    "zip": "81746-73461"
                }, 
                "name": "Department of Gastroenterology, Alzahra Hospital"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluating The Effects of Probiotics on Symptoms of Patients With Irritable Bowel Syndrome", 
        "overall_official": {
            "affiliation": "Isfahan University of Medical Sciences", 
            "last_name": "Somaye Farzamnia, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Abdominal pain was assessed by Rome III questionnaire at baseline and then after 6 weeks", 
            "measure": "Abdominal pain", 
            "safety_issue": "No", 
            "time_frame": "Up to 6 weeks"
        }, 
        "reference": {
            "PMID": "19277023", 
            "citation": "Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009 Apr;104(4):1033-49; quiz 1050. doi: 10.1038/ajg.2009.25. Epub 2009 Mar 10. Review."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01837472"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Isfahan University of Medical Sciences", 
            "investigator_full_name": "Ali Gholamrezaei", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Quality of life was assessed by the IBS-QOL questionnaire at baseline and then after 6 weeks.", 
            "measure": "Quality of Life", 
            "safety_issue": "No", 
            "time_frame": "Up to 6 weeks"
        }, 
        "source": "Isfahan University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Isfahan University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}